EXECUTION VERSION
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
Exhibit 10.2
AMENDMENT NO. 1 TO COMMERCIAL SUPPLY AGREEMENT
(Roxadustat)
This Amendment No. 1 to the Commercial Supply Agreement (the “Agreement”) dated January 1, 2020 (“Effective Date”), is made and entered into as of January 1, 2023 (“Amendment No. 1 Effective Date”) by and between FibroGen, Inc. and its Affiliates (collectively, “FibroGen”), with offices located at 409 Illinois Street, San Francisco, California 94158, and Catalent Pharma Solutions, LLC (“Catalent”), a Delaware limited liability corporation, having an address at 14 Schoolhouse Road, Somerset, New Jersey 08873. FibroGen and Catalent may be referred to individually as a “Party”, and collectively as the “Parties”.
WHEREAS, the Parties wish to clarify and modify certain terms and conditions of the Agreement under this amendment (the “Amendment No. 1”), which are hereby incorporated by reference as though fully set forth herein; and
WHEREAS, FibroGen has engaged Catalent to perform Manufacturing Services, including without limitation the manufacture and supply of roxadustat bulk drug product, and Catalent desires to continue to provide such services, on the terms set forth below.
NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereto agree as follows:
In Witness Whereof, the Parties have caused this Agreement to be executed as of the Effective Date.
REF: 00033430.1
Confidential
1.
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
EXECUTION VERSION
Catalent Pharma Solutions, LLC |
| Fibrogen, Inc. | ||
|
|
|
|
|
By: | /s/ [*] |
| By: | /s/ [*] |
Name: | [*] |
| Name: | [*] |
Title: | [*] |
| Title: | [*] |
Date: | 08-Feb-2023 |
| Date: | 2023-Feb-09 |
REF: 00033430.1
Confidential
2.
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
AMENDMENT NO. 1 ATTACHMENT A
UNIT PRICING, PURCHASE ORDERS AND ADDITIONAL FEES
[*]
UNIT PRICING – [*]
[*]